The S&P 500 will trade in a range that implies the index dropping as much as 8% or rising a little over 1% in the coming ...

Pharmaceuticals stock, reducing the price target from $1,185.00 to $1,150.00. Despite the decrease, the firm maintained its Overweight rating on the NASDAQ-listed company. According to InvestingPro ...

Morgan Stanley (NYSE:MS) upgraded Syensqo SA (SYENS:BB) stock from Underweight to Overweight, significantly raising the price target from EUR66.00 to EUR89.00. The revision reflects the firm's ...

Morgan Stanley has finally conceded that Palantir Technologies is not a stock to sell, but its analysts aren't quite ready to ...

Morgan Stanley Wealth Management (MSWM) is seeing a stall in the S&P 500 ( SP500 ), and said the Federal Reserve halting its ...

Fresh off of his stellar year in 2024, Dennis Lynch is Business Insider's Investor of the Month for January.

Merck &Company Inc (NYSE:MRK) shares tumbled more than 10% Tuesday after reporting mixed fourth-quarter results, with earnings falling short of expectations, revenue surpassing estimates and full-year ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

A Wall Street analyst sees more upside for Nvidia (NASDAQ: NVDA) stock despite the equity facing uncertainty amid escalating ...

Palantir has seen a remarkable surge following its latest earnings report, closing Monday at $83.74, up 1.52% for the day.

A group of Morgan Stanley-led banks is set to increase a sale of loans tied to Elon Musk's social media platform X after ...

In a report released today, Bob Huang from Morgan Stanley maintained a Hold rating on Marsh & Mclennan Companies (MMC – Research Report), ...